VitriVax, a biotechnology company developing next-generation vaccine formulation technologies, announced it has raised $17.25 million in Series B financing. The round was co-led by Adjuvant Capital and RA Capital Management, LP, with proceeds directed toward scaling the company’s clinical and regulatory operations and advancing its proprietary Atomic Layering Thermostable Antigen and Adjuvant (ALTA) platform.
The funding marks a significant milestone for VitriVax as it continues developing its thermostable, single-dose vaccine technology aimed at improving global immunization coverage. The company’s ALTA platform is designed to eliminate the need for cold-chain logistics while enabling single-shot vaccine formulations for diseases that currently require multiple doses. This breakthrough approach could greatly expand access to vaccines in regions where storage and multi-visit administration remain significant barriers to effective immunization.
With this new capital, VitriVax plans to accelerate its regulatory and clinical roadmap, including preparing for first-in-human trials of vaccines formulated with ALTA. The company will also strengthen its manufacturing capabilities to meet the demands of large-scale production and distribution.
The Series B financing follows a $9.9 million grant from the Gates Foundation, which is supporting the aseptic manufacturing of ALTA technology and the establishment of Phase 1-ready GMP production. VitriVax has also received support from the Coalition for Epidemic Preparedness Initiatives (CEPI) and a multi-year contract from the U.S. Department of Defense, demonstrating strong institutional backing for its mission to improve vaccine accessibility and resilience worldwide.
KEY QUOTES:
“The completion of our Series B financing marks an important milestone for VitriVax as we continue to advance the development of ALTA, our thermostable, single-shot vaccine platform. This funding positions us well to execute on our regulatory and clinical strategies, bringing us closer to addressing critical needs in vaccine access and immunization coverage.”
Romulo Colindres, Chief Executive Officer, VitriVax
“We are pleased to support VitriVax as they work to address critical challenges in vaccine development and delivery. Thermostable, single-administration products have the potential to shift the paradigm in how vaccines are distributed and administered, potentially accelerating many long-sought public health goals.”
Glenn Rockman, Founder and Managing Partner, Adjuvant Capital
